ReviewJournal of mammary gland biology and neoplasia1997
ErbB receptors and EGF-like ligands: cell lineage determination and oncogenesis through combinatorial signaling.
Review in Journal of mammary gland biology and neoplasia, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 114 citations in OpenAlex.
- Molecular Basis of Hydatidiform Moles-A Systematic Review.International journal of molecular sciences · 2024Pooled it
- Receptor-Mediated Targeted Delivery of Surface-ModifiedNanomedicine in Breast Cancer: Recent Update and Challenges.Pharmaceutics · 2021Review
- Cardiac monitoring in HER2-positive patients on trastuzumab treatment: A review and implications for clinical practice.Breast (Edinburgh, Scotland) · 2020Review
- Immunohistochemical HER2 Status Evaluation in Breast Cancer Pathology Samples: A Multicenter, Parallel-Design Concordance Study.European journal of breast health · 2018Article
- Article
- Article
- scFv-based "Grababody" as a general strategy to improve recruitment of immune effector cells to antibody-targeted tumors.Cancer research · 2013Article
- Neuregulin promotes incomplete autophagy of prostate cancer cells that is independent of mTOR pathway inhibition.PloS one · 2012Article
- Vitamin D inhibition of TACE and prevention of renal osteodystrophy and cardiovascular mortality.The Journal of steroid biochemistry and molecular biology · 2010Review
- Serum HER-2 concentration is associated with insulin resistance and decreases after weight loss.Nutrition & metabolism · 2010Article
- Exact model reduction of combinatorial reaction networks.BMC systems biology · 2008Article
- Conservation of sleep: insights from non-mammalian model systems.Trends in neurosciences · 2008Review
- Article
- ErbB4/HER4: role in mammary gland development, differentiation and growth inhibition.Journal of mammary gland biology and neoplasia · 2008Review
- EGFR activation increases parathyroid hyperplasia and calcitriol resistance in kidney disease.Journal of the American Society of Nephrology : JASN · 2008Article
- Neuregulins rescue PC12-ErbB-4 cells from cell death induced by beta-amyloid peptide: involvement of PI3K and PKC.Journal of molecular neuroscience : MN · 2005Article
- The role of the ubiquitination-proteasome pathway in breast cancer: ubiquitin mediated degradation of growth factor receptors in the pathogenesis and treatment of cancer.Breast cancer research : BCR · 2003Review
- Neuregulin induces sustained reactive oxygen species generation to mediate neuronal differentiation.Cellular and molecular neurobiology · 2001Article
- Effects of in vivo heregulin beta1 treatment in wild-type and ErbB gene-targeted mice depend on receptor levels and pregnancy.The American journal of pathology · 2001Article
- Inactivation of p53 tumor suppressor gene acts synergistically with c-neu oncogene in salivary gland tumorigenesis.Oncogene · 2001Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The ErbB/HER family of transmembrane receptor tyrosine kinases includes four members that bind more than two dozens ligands sharing an epidermal growth factor- (EGF)3 like motif. This family plays a pivotal role in cell lineage determination in a variety of tissues, including mesenchyme-epithelial inductive processes and the interactions between neurons and muscle, glia and Schwann cells. Certain ligands and receptors of the family, especially the ErbB-2 receptor tyrosine kinase, contribute to a relatively virulent phenotype of some human tumors; most notable are carcinomas of secretory epithelia. This large variety of biological signals is generated through a combinatorial network of signal transduction in which different ErbB ligands are apparently capable of stabilizing discrete homo- and heterodimeric receptor complexes, each coupled to a specific set of cytoplasmic signaling proteins. Because each receptor is unique in terms of catalytic activity, cellular routing and transmodulation, the resulting network allows not only an enormous potential for signal diversification but also fine tuning and stringent control of cellular functions. ErbB-2 emerges as a master coordinator of the network, prolonging and amplifying signaling by decelerating the dissociation rates of its heterologous ligands. Thus, the tumorigenic action of ErbB-2 may be attributed to its ability to act as a shared signaling subunit, rather than by functioning as a bone fide receptor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.